RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the issuance of patent number US 7,169,381, entitled “Colon Cleaning Compositions and Methods,” by the United States Patent and Trademark Office. This patent provides patent coverage until September 1, 2024 to the dry purgative composition containing PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution, that we market in the United States under the trade name MOVIPREP®. Norgine has licensed rights, including this patent, to MOVIPREP in the United States to Salix Pharmaceuticals. The patent has composition of matter claims covering the MOVIPREP purgative that will be listed in the Orange Book.
